Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

byBenzinga Newsdesk

October 17, 2022

1 minute read

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

SelectQuote Stock Slides After Mixed Q4 Results

By Anusuya Lahiri

September 13, 10:10 AM

SelectQuote, Inc (NYSE: SLQT) reported fourth-quarter FY23 revenue growth of 59% year-on-year to $221.78 million, beating the

SLQT

Keefe, Bruyette & Woods Maintains Market Perform on Community Financial, Lowers Price Target to $42

By Benzinga Newsdesk

March 3, 9:22 AM

Keefe, Bruyette & Woods analyst Catherine Mealor maintains Community Financial (NASDAQ:TCFC) with a Market Perform and lowers the price target from $45 to $42.

TCFC

Media
News

Spotify Set to Deepen Audiobook Ambitions: Free Trials for Paying Subscribers

By Anusuya Lahiri

September 8, 9:31 AM

To diversify its offerings, Spotify Technology S.A. (NYSE: SPOT) plans to introduce a monthly pilot program that offers up to 20 hours of free audiobooks to its paying subscribers.

AAPL

Tech Enthusiasts, Looking For The Perfect Holiday Gift? Munster Has These Recommendations For You

By Shanthi Rexaline

December 10, 2:11 PM

With the holiday season in full swing, Gene Munster's Deepwater Asset Management has offered its annual gift ideas.

XLK

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Related Posts

SelectQuote Stock Slides After Mixed Q4 Results

Keefe, Bruyette & Woods Maintains Market Perform on Community Financial, Lowers Price Target to $42

Spotify Set to Deepen Audiobook Ambitions: Free Trials for Paying Subscribers

Tech Enthusiasts, Looking For The Perfect Holiday Gift? Munster Has These Recommendations For You